The acquisition of High Purity New England (HPNE) will advance Getinge’s strategic approach to expand its presence in the biopharma space, says firm. Swedish company Getinge will acquire 100% of the shares in HPNE, which amounts to a $120 million cash payment once the deal has closed. Additionally, if performance milestones are achieved between 2023 to 2025, there is the potential to earn a further $170 million. HPNE, a supplier of equipment and solutions for the biopharmaceutical sector, offers drug…

“We have acquired Synaffix to strengthen our CDMO offering for antibody-drug conjugate (ADC) services, including enhancing our discovery research offering,” says Lonza. Lonza has paid €100 million ($107 million) upfront to acquire Dutch firm Synaffix, adding an ADC technology platform and R&D capabilities, including payload and site-specific linker technology. A further €60 million could be laid out based on additional performance-based consideration. “The acquisition expands our ADC services to include development technology, including payload and site-specific linker technology, completing an…